China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd has reportedly secured more than USD 20 million in a Series A+ financing round. Cherami Investment led the investment, which will be utilized to enhance drug development efforts and to upgrade and commercialize the company’s AI drug development platform.
Upgrading the AI Drug Development Platform
The proceeds from the financing round will be directed towards the advancement of MindRank’s drug development initiatives and the enhancement of their AI platform, further solidifying the company’s position at the forefront of AI-driven drug development.
Molecule Pro: A Pioneering AI Drug Development Platform
MindRank boasts its in-house developed one-stop AI drug development platform, Molecule Pro, which has demonstrated remarkable efficiency in drug development processes. A prime example is the company’s small molecule GLP-1 receptor agonist, MDR-001, which obtained clinical trial approval just 19 months from the initiation of the program. The Phase I study for this compound commenced last month, highlighting the speed and effectiveness of MindRank’s AI-driven approach.-Fineline Info & Tech
